Peptide
Reference library
Educational peptide reference — research use only.
Research & educational use only
For laboratory and educational research only. Not for human or veterinary consumption. This is not medical advice. Always follow applicable laws and consult qualified professionals.
The calculator performs unit math for research reference. It must not be used to plan or guide dosing in humans or animals. Verify all figures independently in your lab protocol.
Triptorelin Acetate
A GnRH agonist studied in prostate and reproductive endocrine research.
- Half-life (approx.)
- ~3 h (approx.)
- Diluent
- Bacteriostatic water (0.9% benzyl alcohol)
- Common vials
- 0.1, 2 mg
Half-life figures are literature approximations for educational reference — not pharmacokinetic advice.
Overview
Triptorelin is a GnRH agonist that initially stimulates then desensitizes gonadotropin release, used in prostate-cancer and endometriosis research. Low-dose pulse protocols differ pharmacologically from sustained high-dose suppression. Sustained-release GnRH agonist for androgen deprivation and endometriosis suppression research.
Structure & identity
GnRH decapeptide D-Phe-GnRH analog
- Sequence / structure
- GnRH decapeptide D-Phe-GnRH analog
Status: FDA-approved (Trelstar, others).
Mechanism
FDA-approved (Trelstar, others).
GnRH agonist causes initial LH/FSH flare then receptor downregulation with chronic use. Initial flare then receptor downregulation defines chronic vs pulsatile gonadorelin pharmacology.
Studies & clinical programs
Prostate cancer androgen deprivation
Published research models
- Peer-reviewed literature documents endpoints under Prostate cancer androgen deprivation experimental designs.
Endometriosis suppression
Published research models
- Peer-reviewed literature documents endpoints under Endometriosis suppression experimental designs.
Research models in literature
- Prostate cancer androgen deprivation
- Endometriosis suppression
Literature highlights
- GnRH agonist causes initial LH/FSH flare then downregulation in chronic administration models.
- Prostate cancer and endometriosis suppression trials use sustained-release formulations.
- FDA-approved GnRH analog — pulsatile vs chronic dosing literature is mechanistically distinct.
Key targets & pathways
Research areas
Routes in research literature
Also known as
Stability & storage phases
| Phase | Condition | Guidance |
|---|---|---|
| Lyophilized | Sealed vial, refrigerated (2–8 °C) | Intact lyophilized cake or powder is typically stable for months to years per published stability data; protect from moisture, light, and repeated freeze-thaw of the dry vial. |
| Reconstituted | Bacteriostatic water (0.9% benzyl alcohol), refrigerated | Most aqueous peptide solutions remain usable for approximately 2–4 weeks refrigerated; verify published stability data and label with reconstitution date. |
| Working aliquots | Pre-drawn syringes or microtubes, frozen (−20 °C) | Aliquot promptly after mixing to limit freeze-thaw cycles on the main vial; thaw once and use to reduce protease-mediated degradation. |
Stability windows are formulation-dependent — verify published data and your lab SOP.
Reconstitution reference table
| Vial (mg) | Diluent (mL) | mcg/mL | Units @ 100 mcg | Units @ 250 mcg | Units @ 500 mcg |
|---|---|---|---|---|---|
| 0.1 | 1 | 100.0 | 100 | 250 | 500 |
| 2 | 1 | 2000.0 | 5 | 12.5 | 25 |
U-100 insulin syringe scale (100 units = 1 mL). Illustrative only — not dosing guidance.
Reconstitution steps
- Allow vial to reach room temperature (15–30 min)
- Swab rubber stopper with alcohol prep pad
- Draw calculated bacteriostatic water into syringe
- Inject diluent slowly down vial wall — do not spray directly onto cake
- Gently swirl until fully dissolved — do not shake vigorously
- Label with date, concentration, and diluent volume
- Refrigerate and use within your lab stability window
Low-dose vials common; reconstitute per label and protocol.
Laboratory record checklist
- Compound identity recorded in lab notebook (name, lot, preparation date)
- Analytical identity cross-checked against published sequence or structure
- Potency or concentration documented from analytical certificate when available
- Purity or HPLC data filed when provided with research material
- Appearance noted: intact lyophilized cake or uniform powder
- Sterility / endotoxin report archived when available
- Storage temperature applied immediately per published stability guidance